Navigation Links
Pennsylvania Department of Health Opens Application Process for Research Funding to Treat Childhood Seizures

HARRISBURG, Pa., Nov. 18, 2015 /PRNewswire-USNewswire/ -- The Department of Health has opened the application process for expanded research into the use of Cannabidiol (CBD) for the treatment of children with intractable seizures.

Qualified research facilities are invited to compete for $2 million in funding from the Commonwealth Universal Research Enhancement Program (CURE) to support the study of CBD in treating children with epilepsy and other neurological diseases who suffer from medication-resistant seizures.

In November 2014, $2 million in CURE funding from the Tobacco Master Settlement Agreement of 1998 was placed in budgetary reserve for so-called "non-formula" priorities.

Following the success of several small pilot studies, the Department of Health determined that the continued study of CBD for the treatment of seizure frequency would be a priority for the agency.

"Treatment-resistant seizures are especially tragic when they affect children. The inability to control or stop seizure activity has a devastating impact on quality of life of pediatric patients," said Health Secretary Karen Murphy. "The goal of funding this research is to provide expanded – and compassionate -- access to CBD for children with intractable seizures in the hope that they are relieved of their pain and suffering."

The department has entered into an agreement with a manufacturer of pharmaceutical grade CBD. This manufacturer will provide a course of treatment for fifty pediatric patients at no cost to the awardee. The drug, in turn, must be provided to the study participant at no cost. The awardees will work directly with the manufacturer to secure, manage, and distribute the drug in accordance with its United States Food and Drug Administration's (FDA) approved expanded access drug status.

The funding will be made available in the summer of 2016.

CBD is a natural cannabinoid and one of over 400 natural chemical compounds found within the Cannabis Sativa plant. When isolated, the CBD compound has no psychotropic effects in humans and initial studies indicate it may possess a variety of pharmaceutical benefits, including reduction in seizure frequency.

The Request for Applications (RFA) document is posted on the Department of General Services emarketplace website at The deadline is December 8.

MEDIA CONTACT: Amy Worden, DOH, 717-787-1783


SOURCE Pennsylvania Department of Health
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Pennsylvania Physicians Urge State Legislators to Support Immunization Expansion Bill
2. Report: Upgrading Medicaid Drug Benefits Could Save Pennsylvania $896 Million
3. Wrong-Patient Medication Errors Examined by the Pennsylvania Patient Safety Authority
4. Center for Organ Recovery & Education Renews Call for Pennsylvania State Lawmakers to Support Donate Life PA Act
5. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
6. Pennsylvania Governor Corbett: Specialized Medical Company to Relocate Headquarters and Customer Service Center
7. Pharmacy Access Coalition Urges Pennsylvania General Assembly to Support Measure Expanding Access to Vaccines
8. Pennsylvania Department of Drug and Alcohol Programs Urges Participation in National Drug Take Back Day Events This Week
9. Highmark executive Michael Fiaschetti Appointed to Board of Pennsylvania eHealth Partnership Authority
10. Stakeholders elect ex-officio members to Board of Pennsylvania eHealth Partnership Authority
11. New Pennsylvania Hospital Opens, MEMdata Equipment Planning Utilized
Post Your Comments:
(Date:9/17/2019)... Zealand (PRWEB) , ... September 17, 2019 , ... Called ... in Fast Company’s 2019 Innovation by Design Awards Students category. , It was developed ... the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor bit” ...
(Date:9/17/2019)... ... 17, 2019 , ... Scientists writing in a 2017 issue ... the progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... limb orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer ...
(Date:9/17/2019)... ... , ... Today, in partnership with Lehman College, Power to ... student and faculty from The City University of New York (CUNY). The panel ... Schuster, MPH; Raffaele M. Bernardo, DO, FACP, AAHIVS and Stuart Chen-Hayes, PhD. In ...
Breaking Medicine Technology:
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... to join the largest accountable care organization (ACO) in the country, the company ... this groundbreaking collaboration to improve care quality and increase cost efficiency. This opportunity ...
(Date:9/17/2019)... ... 17, 2019 , ... Dr. Perry Patel, the dentist ... the American Academy of Facial Esthetics (AAFE) to administer Botox and dermal filler ... conditions such as tooth clenching and grinding, tongue tension, temporomandibular joint disorders, commonly ...
(Date:9/17/2019)... ... September 17, 2019 , ... The Center for Information ... of the third edition of The Gift of Participation. Written by CISCRP Founder, ... families to navigate the clinical research process. The new edition offers a fresh ...
(Date:9/14/2019)... (PRWEB) , ... September 13, ... ... Society (WMIS) showcased several first-in-human studies on the detection and treatment of ... two examples of these ground-breaking studies were noninvasive detection of residual HIV ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful ... coronary artery disease as he hopes to prevent anyone from having it and to ... author John Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to ...
Breaking Medicine News(10 mins):